Tests NGM120 in people with colorectal cancer and cancer cachexia
Tests NGM120 against placebo in adults with colorectal cancer and cancer cachexia.
Key facts
- Who runs it
- NGM Biopharmaceuticals, Inc
- Where
- Cracow, Lodz, Poznan, Warsaw, and Wroclaw, PolandSee the 7 sitesAlso in 8 other countries, 38 sites
- Trial code
- Registry title
- An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 136 people, planned
- Started
- 25 Jun 2025
- Expected to end
- Dec 2027
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- NGM120 Q4W
- NGM120 Q8W
- Placebo given
- Record updated
- 1 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with active colorectal cancer who have lost weight because of cancer cachexia (cancer-related wasting).
- Age
- 18 years and older
- Sex
- All sexes can join
- Disease stage
- Active colorectal cancer with cachexia, defined by the Fearon criteria of weight loss
Main reasons for not taking part
- Current reversible causes of eating less
- Tube feeding or nutrition through a vein at Screening or Randomization
- Cachexia caused by other reasons
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Documented active diagnosis of colorectal cancer
- Cachexia defined by Fearon criteria of weight loss
- Signed informed consent
Who cannot take part
- Receiving tube feedings or parenteral nutrition at the time of Screening or Randomization
- Current active reversible causes of decreased food intake
- Have cachexia caused by other reasons
Where in Poland
Also in 8 other countries, 38 sites
- Futuremeds Sp. z o.o.Cracow, PolandTaking people
- Pratia S.A.Cracow, PolandTaking people
- Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o.Cracow, PolandTaking people
- Futuremeds Sp. z o.o.Lodz, PolandTaking people
- Pratia S.A.Poznan, PolandTaking people
- Futuremeds Sp. z o.o.Warsaw, PolandTaking people
- Futuremeds Sp. z o.o.Wroclaw, PolandTaking people
About the trial
What the trial wants to find out
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
The 5 groups in the trial
- NGM120 Treatment Group ATreatment being tested
NGM120 low dose given subcutaneously every 4 weeks
Treatment: NGM120 Q4W
- NGM120 Treatment Group BPlacebo, for comparison
Placebo low dose given subcutaneously every 4 weeks
Treatment: Placebo given
- NGM120 Treatment Group CTreatment being tested
NGM120 high dose given subcutaneously every 4 weeks
Treatment: NGM120 Q4W
- NGM120 Treatment Group DTreatment being tested
NGM120 high dose given subcutaneously every 8 weeks
Treatment: NGM120 Q8W
- NGM120 Treatment Group EPlacebo, for comparison
Placebo high dose given subcutaneously every 4 weeks
Treatment: Placebo given
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 2, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants With Colorectal Cancer Who Have Cancer Cachexia
- Plain-language title
- Tests NGM120 in people with colorectal cancer and cancer cachexiaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 1 April 2026